Baseline characteristics
| Group A | Group B | Group C | Group D | |
|---|---|---|---|---|
| Values are mean (SD) unless stated. | ||||
| Group A: patients with hypertrophy confined to the septum; group B: patients with hypertrophy confined to the septum and left ventricular anterior wall; group C: patients with hypertrophy confined to the septum, left ventricular anterior wall, and lateral wall; group D: patients with hypertrophy of all portions of the left ventricle. | ||||
| *p < 0.001 v group D; †p < 0.05 v group D. | ||||
| ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; FS, fractional shortening; IVST, interventricular septal thickness; LAD, left atrial dimension; LVDd, left ventricular end diastolic dimension; LVDs, left ventricular end systolic dimension; maxWT, maximum LV wall thickness; PWT, left ventricular posterior wall thickness; SCD, sudden cardiac death; VT, ventricular tachyarrhythmia. | ||||
| Number of cases | 9 | 21 | 26 | 14 |
| Male | 7 (78%) | 16 (76%) | 20 (77%) | 12 (86%) |
| Age (years) | 56 (18) | 54 (15) | 56 (14) | 61 (9) |
| History of syncope | 1 (11%) | 3 (15%) | 4 (15%) | 2 (14%) |
| Family history of SCD | 1 (11%) | 6 (30%) | 6 (22%) | 7 (50%) |
| VT | 2 (22%) | 3 (14%) | 3 (13%) | 1 (7%) |
| Echocardiogram | ||||
| maxWT (mm) | 17.7 (4.4) | 19.7 (4.0) | 20.0 (4.9) | 17.9 (5.1) |
| IVST (mm) | 16.6 (3.2) | 18.2 (3.6) | 18.9 (4.6) | 17.6 (5.2) |
| PWT (mm) | 11.0 (1.5)* | 12.0 (1.4)* | 12.1 (2.1)* | 14.7 (1.4) |
| IVST/PWT | 1.55 (0.48) | 1.55 (0.34)† | 1.57 (0.30)† | 1.19 (0.28) |
| LAD (mm) | 39.7 (4.5) | 40.0 (7.9) | 39.6 (6.4) | 39.6 (6.8) |
| LVDd (mm) | 46.7 (7.3) | 44.2 (7.2) | 45.1 (5.5) | 44.3 (5.3) |
| LVDs (mm) | 30.0 (5.2) | 26.2 (7.2) | 27.5 (4.4) | 26.8 (3.8) |
| FS (%) | 35.7 (5.3) | 41.1 (9.9) | 39.0 (6.4) | 42.0 (9.6) |
| Drug treatment | ||||
| β Blocker | 2 (22%) | 3 (15%) | 8 (30%) | 2 (14%) |
| Calcium antagonist | 4 (44%) | 8 (40%) | 12 (44%) | 2 (14%) |
| ACEI or ARB | 1 (11%) | 3 (14%) | 2 (8%) | 4 (29%) |
| Amiodarone or sotalol | 0 | 0 | 1 (4%) | 0 |